Atty Dkt. No.: STAN-316 USSN: 10/528,377

## AMENDMENTS TO THE CLAIMS:

(Currently amended) A method comprising:

contacting a hepatitis C virus (HCV) NS4B nucleotide binding motif (NBM) polypeptide with a candidate agent; and

determining an effect of said candidate agent on a GTPase activity of said polypeptide;

and

## determining an effect of said candidate agent on replication of HCV.

- (Canceled)
- (Previously presented) The method of claim 1, wherein said method further comprises determining an effect of said candidate agent on nucleotide binding of said polypeptide.
  - 4. (Canceled)
- 5. (Previously presented) The method of claim 1, wherein said method further comprises determining an effect of said candidate agent on RNA binding of said polypeptide.
  - 6. (Original) The method of claim 1, wherein said candidate agent is a nucleotide analog.
- (Original) The method of claim 6, wherein said nucleotide analog is a non-hydrolysable nucleotide.
  - (Canceled).
- (Currently amended) The method of <u>claim 1</u> elaim 8, wherein said HCV is a subgenomic or full length HCV replicon.

Atty Dkt. No.: STAN-316 USSN: 10/528,377

10. (Currently amended) The method of claim 1 elaim 8, further comprising wherein said method comprises determining an effect of said candidate agent on testing HCV replication in a huh? cell.

## 11-21, (Canceled)

- (Currently Amended) The method of <u>claim 1 elaim 8</u>, wherein said method comprises assaying said candidate agent on HCV replication in a liver cell line or primary liver cell.
- 23. (Currently Amended) The method of claim 9, wherein <u>said aid-HCV</u> is live virus or a replicon thereof.